Reviewing Profusa (PFSA) & Its Peers

Profusa (NASDAQ:PFSA – Get Free Report) is one of 510 public companies in the “Healthcare Equipment & Supplies” industry, but how does it weigh in compared to its rivals? We will compare Profusa to related businesses based on the strength of its valuation, institutional ownership, profitability, analyst recommendations, earnings, risk and dividends.

Profitability

This table compares Profusa and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Profusa N/A N/A -252.60%
Profusa Competitors -191.42% -197.84% -21.82%

Institutional and Insider Ownership

9.8% of Profusa shares are held by institutional investors. Comparatively, 40.3% of shares of all “Healthcare Equipment & Supplies” companies are held by institutional investors. 15.0% of Profusa shares are held by insiders. Comparatively, 14.9% of shares of all “Healthcare Equipment & Supplies” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of recent ratings for Profusa and its rivals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Profusa 1 0 0 0 1.00
Profusa Competitors 4323 10552 18353 839 2.46

As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 27.64%. Given Profusa’s rivals stronger consensus rating and higher possible upside, analysts clearly believe Profusa has less favorable growth aspects than its rivals.

Earnings & Valuation

This table compares Profusa and its rivals gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Profusa N/A -$35.82 million -0.00
Profusa Competitors $1.90 billion $138.28 million 5.84

Profusa’s rivals have higher revenue and earnings than Profusa. Profusa is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Volatility & Risk

Profusa has a beta of 0.62, indicating that its share price is 38% less volatile than the S&P 500. Comparatively, Profusa’s rivals have a beta of 2.58, indicating that their average share price is 158% more volatile than the S&P 500.

Summary

Profusa rivals beat Profusa on 10 of the 13 factors compared.

Profusa Company Profile

(Get Free Report)

Profusa is a medical technology company developing biosensors designed to measure changes in the body’s chemistry continuously. Its platform uses small, tissue-integrated sensors that generate signals a wearable reader can detect and relay for analysis. The company’s Lumee Oxygen platform is designed to monitor oxygen levels in tissue. Profusa has focused on applications where local oxygen measurements may help clinicians assess tissue health, including care involving peripheral artery disease. Profusa’s technology combines its biosensors with reader and software components to collect and display measurement data.

Receive News & Ratings for Profusa Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Profusa and related companies with MarketBeat.com's FREE daily email newsletter.